Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
Fortune on MSN5d
Danish town where weight-loss wonder drug Ozempic is made suffers from the highest rates of overweight children in DenmarkA more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback